• Home
  • About APS
  • APS News
  • Job Postings and Ads
  • Events and Education
  • Goverment Affairs
  • 2024 Annual Meeting
  • Education-OUD
  • Education-On Demand
  • Mental Health Resources

To Buy Strattera Online Visit Our Pharmacy ↓

Click HERE To Buy Strattera Online ↓




  • **strattera Vs. Stimulants: Which Is Better?**

    Understanding Strattera: Mechanism and Benefits Explained


    Strattera, or atomoxetine, operates as a selective norepinephrine reuptake inhibitor, targeting neurotransmitters in the brain to enhance focus and attention. Unlike traditional stimulants, it does not stimulate the central nervous system, making it a non-controlled substance. This allows for a different approach to treating Attention Deficit Hyperactivity Disorder (ADHD), particularly for those who may not respond well to stimulants or desire an alternative without addictive potential.

    One of the notable benefits of Strattera is its extended efficacy. Many users report that it can help maintain attention and reduce impulsivity throughout the day without the peaks and troughs commonly associated with stimulant medications. Additionally, it provides a more gradual onset of effects, which can lead to a lower risk of side effects such as insomnia or jitteriness.

    Moreover, Strattera is often praised for being suitable for a wider range of patients, including those with coexisting conditions like anxiety disorders. Its distinct mechanism can lead to a more stable mood and decreased anxiety in some individuals, offering a holistic approach to managing ADHD symptoms. Understanding its unique benefits makes it easier for patients and physicians to weigh it against stimulant options.

    ```html

    Feature Strattera Stimulants
    Type Non-stimulant Stimulant
    Mechanism Norepinephrine reuptake inhibitor Dopamine and norepinephrine release
    Duration of Action Long-acting Short to long-acting based on type
    Addictive Potential None Potentially high
    ```



    Exploring Stimulants: Types and Their Effectiveness



    Stimulants are commonly prescribed medications that primarily focus on enhancing the levels of certain neurotransmitters in the brain, particularly dopamine and norepinephrine. Popular options such as methylphenidate and amphetamines have been shown to improve attention and reduce hyperactive behaviors swiftly, often yielding noticeable results within hours of consumption. These medications are effective for many individuals, quickly addressing the symptoms associated with Attention Deficit Hyperactivity Disorder (ADHD).

    While stimulant medications offer significant benefits, they can also lead to varying effects on individuals. Some may experience increased focus and energy, while others might encounter jitteriness or anxiety. In contrast to Strattera, which operates through a different mechanism, stimulants tend to have a more immediate impact on concentration and productivity. Understanding these distinctions can help individuals and healthcare providers make informed decisions tailored to each person's needs.



    Side Effects Comparison: Strattera Vs. Stimulants


    When comparing the side effects of strattera and stimulant medications, it becomes clear that each has its unique profile. Strattera, a non-stimulant option, often has milder side effects such as fatigue, decreased appetite, and nausea. These effects tend to diminish over time, making it a suitable choice for some individuals seeking a more stable experience without the highs and lows associated with stimulants.

    On the other hand, stimulants like methylphenidate and amphetamines can lead to more pronounced side effects, including increased heart rate, insomnia, and anxiety. While they are often more effective in managing symptoms of ADHD for many, their potential for addiction and withdrawal can deter some users.

    Ultimately, the choice between strattera and stimulants depends on personal tolerance and lifestyle considerations. Those with a history of anxiety or cardiovascular issues may prefer strattera, while others may gravitate towards the immediate effects offered by stimulants. Individual experiences with side effects can vary significantly, highlighting the importance of consulting a healthcare professional for tailored guidance.



    Duration of Action: How Long Do They Last?



    When considering treatment options for ADHD, one important factor is how long the medication lasts. Strattera, an FDA-approved non-stimulant, typically has a longer duration of action, as its effects can last up to 24 hours with once-daily dosing. This allows for consistent symptom management throughout the day, which may suit individuals who prefer a steady, sustained response without the peaks and troughs often associated with stimulant medications.

    In contrast, stimulant medications, such as Adderall and Ritalin, come in both short-acting and long-acting formulations. Short-acting stimulants may work for around 4 to 6 hours, while extended-release versions can provide relief for up to 12 hours, yet they may not cover the full day as effectively as Strattera for some users. The choice between these options often hinges on one's daily schedule and the timing of symptom control required.

    Ultimately, understanding how long each medication lasts can significantly impact quality of life for those managing ADHD. Individuals might find that shorter durations of stimulants fit their needs for specific time frames, while the extended efficacy of Strattera can offer a seamless approach for ongoing daily activities, allowing users to thrive without interruption.



    Individual Responses: Choosing the Right Medication


    When it comes to selecting the right medication for ADHD, individual responses can greatly vary, making personal experiences essential in the decision-making process. While Strattera, a non-stimulant option, offers a unique mechanism of action by targeting norepinephrine levels, stimulant medications like Adderall and Ritalin work more directly on dopamine pathways. This fundamental difference can lead to distinct effectiveness for different individuals based on their specific neurochemistry.

    Some users of Strattera report a smoother, more manageable experience with fewer peaks and valleys compared to the potential highs and lows associated with stimulant medications. However, others find stimulants provide rapid relief of symptoms, making them appealing for those seeking immediate results.

    To help navigate these choices, consider a brief overview of their unique characteristics in the table below:

    Medication Type Mechanism Onset of Action
    Strattera Norepinephrine reuptake inhibitor Days to weeks
    Stimulants Dopamine reuptake inhibitor Minutes to hours

    Ultimately, the choice between Strattera and stimulants boils down to personal preference and individual response to treatment. Engaging in discussions with healthcare providers while also considering shared experiences from others can provide invaluable insights.



    Real-life Experiences: Users Share Their Stories


    Many individuals find their path to managing ADHD through personal narratives. Strattera users often highlight its gradual, steady effect as a key benefit, praising the absence of euphoric highs and lows typically associated with stimulants. These users report improvements in concentration and mood stability, appreciating how the medication fits seamlessly into their daily routines.

    On the other hand, stimulant users frequently share stories of immediate and noticeable enhancements in focus and productivity. Many describe the initial rush of clarity and energy they experience, which can transform their engagement in daily tasks. However, this comes with the added pressure of needing to manage side effects, making the choice complex for some.

    Through these distinct experiences, individuals weigh the merits of each approach, looking for what complements their lifestyle best. The journey to find the right medication is often personalized, underscoring the importance of understanding one's own needs and responses in the search for effective ADHD management.





ARIZONA PSYCHIATRIC SOCIETY 2024-2025 EXECUTIVE Board

President: Nicholas Ahrendt, MD President-Elect: Margaret Balfour, MD, PhDVice President: Brenner Freeman, MDTreasurer: Robert Rymowicz, DOSecretary: Chiranjir "Ravi" Narine, MD Co Resident-Fellow Member Representatives: Nehal Samra, MD Creighton Matthew Mitchell, MD UA-PhoenixGagan Singh, MD UA-Tucson
APA Assembly Representatives: Jason Curry, DO (serves term concluding 2024) Jasleen Chhatwal, MBBS, MD (two-year term concluding 2024)Payam Sadr, MD (one-year term concluding 2024) Past President Gagandeep Singh, MD, DFAPA Stephen "Larry" Mecham, DO The Society thanks these members for their leadership.

Celebrating our members

Chase was born and raised in Phoenix, AZ, and attended ASU for a bachelor’s degree in business then attended KCUMB for medical school in Kansas City. He was excited to return home to AZ when he found out he'd been matched with UACOM – Phoenix for his psychiatry residency.
He was first drawn to the field of psychiatry during his years in medical school as he found the psychiatric subject matter and the patients to be the most engaging and interesting of all his studies. He quickly came to realize that without a healthy mind, one is unable to thoroughly experience life constructive way. He wanted to be the person to help those struggling with mental illness as he found these cases and experiences to be the most rewarding in medicine.
Dr. Crookham said he has been lucky enough to have been matched at a great psychiatric residency program where he gets to learn from great mentors and colleagues every day. He believes his passion for psychiatry along with the relationships he's developed with his colleagues and mentors will carry him to be a lifelong learner and devoted psychiatrist for his future patients.
Meghan is a graduate of Lincoln Memorial University, DeBusk College of Osteopathic Medicine.
She received her Bachelor of Arts from the University of Denver in French and Biology with a concentration in Cognitive Neuroscience.
She is currently a chief resident at UACOM-Tucson in her final year of psychiatry training and will be starting a fellowship in Addiction Medicine at the University of Arizona, Tucson in July.
Her professional interests include physician mental health, adult consult liaison and addiction psychiatry.
In her personal time, she enjoys home design projects, spending time with family, learning about plants, and exploring new places.
Dr. Hintze is currently honeymooning in Japan! Congratulations!!
Danny is originally from Phoenix. Graduated from Brophy, ASU, and UA Tucson Medical School. His background is in economics, philosophy of science, and rational decision-making.
He was drawn to psychiatry because of the conceptual complexity and the profound impact even relatively simple pharmaceutical, medical, and psychotherapeutic interventions can have to empower patients and their families.
As a mentor, he wanted to recognize the many people within the Arizona Medical Community, particularly at UA Tucson, Valleywise, and within organized medicine who have worked to protect and promote medicine as a joyful, compassionate, and healing experience for patients and for all of us who help care for them.

ARIZONA PSYCHIATRIC SOCIETY past presidents

Otto L. Bendheim, M.D. 1960-1961Warren S. Williams, M.D. 1961-1963T. Richard Gregory, M.D. 1963-1964Boris Zemsky, M.D. 1964-1965 Hal J. Breen, M.D. 1965-1966Joseph M. Green, M.D. 1966-1967Irene M. Josselyn, M.D. 1967-1968Hubert R. Estes, M.D. 1968-1969Richard H. Bruner, M.D. 1969-1970Thomas F. Kruchek, M.D. 1970-1971David S. Burgoyne Sr., M.D. 1971-1972Marshall W. Jones, M.D. 1972-1973Harold D. Haeussler, M.D. 1973-1974William B. Haeussler, M.D. 1974-1975Edward S. Gelardin, M.D. 1975-1976Hugo L. Cozzi, M.D. 1976-1977Robert F. Meyer, M.D. 1977-1978James E. Campbell, M.D. 1978-1979Stuart M. Gould, M.D. 1979-1980Elliot M. Heiman, M.D. 1980-1981Stephen V. Shanfield, M.D. 1981-1982Jerry A. Biggs, M.D. 1982-1983Robert C. Shapiro, M.D. 1983-1984Dennis C. Westin, M.D. 1984-1985John H. Jarvis, M.D. 1985-1986James G. Hill, M.D. 1986-1987Robert P. Bevan, M.D. 1987-1988Eugene J. Kinder, M.D. 1988-1989 James M. Campbell, M.D. 1989-1990David S. Burgoyne II, M.D. 1990-1991
Stuart W. Hollingsworth, M.D. 1991-1992Kevin J. Leehey, M.D. 1992-1993Stephen S. Brockway, M.D. 1993-1994Michael H. Stumpf, M.D. 1994-1995Lauro Amezcua-Patino, M.D. 1995-1996David S. Burgoyne II, M.D. 1997-1998Glenn Lippman, M.D. 1998-1999Lisa Jones, M.D. 1999-2000David J. Coons, M.D. 2000-2001James M. Campbell, M.D. 2001-2002Bradley Johnson, M.D. 2002-2003David W. Leicken, M.D. 2003-2004Thomas N. Crumbley, M.D. 2004-2006Jeffrey L. Schwimmer, M.D., M.P.H. 2006-2007Stephen O. Morris, M.D. 2007-2008Jack L. Potts, M.D. 2008-2009Elizabeth A. Kohlhepp, M.D. 2009-2010Michael E. Brennan, M.D. 2010-2011Gretchen Alexander, M.D. 2011-2012Tariq M. Ghafoor, M.D. 2012-2013Joanna K. Kowalik, M.D., M.P.H., 2013-2014Payam M. Sadr, M.D., 2014-2015Roland Segal, M.D., 2015-2016Gurjot Marwah, M.D., 2016-2017Aaron Wilson, M.D., 2017-2018Mona Amini, M.D., 2018-2019 Don J. Fowls, M.D., 2019-2020 Jasleen Chhatwal, M.B.B.S., M.D., 2020-2022 Stephen Larry Mecham, DO, 2022-2023 Gagandeep Singh, MD, DFAPA 2023-2024
Main Menu
  • Home
  • About APS
  • APS News
  • Job Postings and Ads
  • Events and Education
  • 2023 Annual Meeting
  • Education-OUD
  • Education-On Demand
  • Mental Health Resources
Contact Information
Address: 2401 West Peoria Avenue, Suite 315 Phoenix, Arizona 85029
Phone: 602-909-4388
E-mail: admin@azpsych.org
Social
The Arizona Psychiatric Society is committed to ensuring the accessibility of its website to people with disabilities. If you have trouble accessing any of the Arizona Psychiatric Society's resources, please contact us at admin@azpsych.org for assistance Copyright © 2020 Network Solutions, LLC, A Web.com Company. All rights reserved.

We use cookies to enable essential functionality on our website, and analyze website traffic. By clicking Accept you consent to our use of cookies. Read about how we use cookies.

Your Cookie Settings

We use cookies to enable essential functionality on our website, and analyze website traffic. Read about how we use cookies.

Cookie Categories
Essential

These cookies are strictly necessary to provide you with services available through our websites. You cannot refuse these cookies without impacting how our websites function. You can block or delete them by changing your browser settings, as described under the heading "Managing cookies" in the Privacy and Cookies Policy.

Analytics

These cookies collect information that is used in aggregate form to help us understand how our websites are being used or how effective our marketing campaigns are.